Clinical Data GlycoMimetics announced initial phase 1 clinical data that of 13 evaluable patients, 8 (62%) showed clinical response to the treatment.  "Of the eight objective responses, seven patients achieved a complete response (CR), with the eighth patient achieving complete response but with an incomplete blood count recovery (CRi)."